LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
+3.1%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$1.39B
AUM Growth
+$1.39B
(+19%)
Cap. Flow
+$232M
Cap. Flow
% of AUM
16.7%
Top 10 Holdings %
Top 10 Hldgs %
54.77%
Holding
73
New
16
Increased
17
Reduced
14
Closed
16
Top Buys
| 1 |
IDEAYA Biosciences
IDYA
|
$45.2M |
| 2 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
$38M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$36.3M |
| 4 |
PMV Pharmaceuticals
PMVP
|
$35.6M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$31.6M |
Top Sells
| 1 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
$31.2M |
| 2 |
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
|
$28.4M |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$15.8M |
| 4 |
Iovance Biotherapeutics
IOVA
|
$15.4M |
| 5 |
VERV
Verve Therapeutics
VERV
|
$14.8M |
Sector Composition
| 1 | Healthcare | 99.99% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
ALX Oncology
ALXO
$62.7M
| $233M | 16.81% | 3,156,981 | – | – |
|
2
Olema Pharmaceuticals
OLMA
$375M
| $103M | 7.44% | 3,743,875 | – | – |
|
|
DCPH
3
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $62.9M | 4.53% | 1,850,000 +750,000 | +68% | +$25.5M |
|
|
BCYC
4
Bicycle Therapeutics
BCYC
$511M
| $61.3M | 4.42% | 1,475,000 +760,000 | +106% | +$31.6M |
|
5
Dyne Therapeutics
DYN
$1.92B
| $58.8M | 4.24% | 3,619,392 +1,565,000 | +76% | +$25.4M |
|
|
KRTX
6
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $56.3M | 4.06% | 460,000 +135,000 | +42% | +$16.5M |
|
|
FMTX
7
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $49M | 3.54% | 2,115,000 +900,000 | +74% | +$20.9M |
|
|
8
Apellis Pharmaceuticals
APLS
$3.48B
| $47.8M | 3.45% | 1,450,000 +1,100,000 | +314% | +$36.3M |
|
|
9
IDEAYA Biosciences
IDYA
$2.15B
| $45.2M | 3.26% | +1,775,000 | New | +$45.2M |
|
|
CMPS
10
Compass Pathways
CMPS
$424M
| $41.8M | 3.02% | 1,400,000 +550,000 | +65% | +$16.4M |
|
|
11
PMV Pharmaceuticals
PMVP
$74.2M
| $41.7M | 3.01% | 1,400,000 +1,193,436 | +578% | +$35.6M |
|
12
Design Therapeutics
DSGN
$315M
| $40.7M | 2.94% | 2,772,501 +40,000 | +1% | +$588K |
|
|
DICE
13
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $38M | 2.74% | +1,160,251 | New | +$38M |
|
14
Cytokinetics
CYTK
$4.23B
| $35.7M | 2.58% | 1,000,000 -400,000 | -29% | -$14.3M |
|
15
Nkarta
NKTX
$151M
| $35.5M | 2.56% | 1,275,777 +273,395 | +27% | +$7.6M |
|
16
Kezar Life Sciences
KZR
$28.9M
| $35.4M | 2.55% | 4,100,000 +1,800,000 | +78% | +$15.6M |
|
17
Aligos Therapeutics
ALGS
$73.3M
| $30.4M | 2.2% | 1,962,785 +1,750,000 | +822% | +$27.1M |
|
|
ARNA
18
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $30.4M | 2.19% | +510,000 | New | +$30.4M |
|
19
Viridian Therapeutics
VRDN
$1.5B
| $24.7M | 1.78% | +1,500,000 | New | +$24.7M |
|
20
Instil Bio
TIL
$182M
| $22.8M | 1.65% | 1,277,091 -419,759 | -25% | -$7.5M |
|
|
VERV
21
DELISTED
Verve Therapeutics
VERV
| $20.8M | 1.5% | 443,265 -315,000 | -42% | -$14.8M |
|
|
LABP
22
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
| $20.5M | 1.48% | 1,405,000 +505,894 | +56% | +$7.39M |
|
|
LENZ
23
LENZ Therapeutics
LENZ
$1.1B
| $19.8M | 1.43% | 1,206,308 +135,546 | +13% | +$2.22M |
|
|
CNTA
24
Centessa Pharmaceuticals
CNTA
$2.25B
| $17.9M | 1.29% | 1,069,545 +130,000 | +14% | +$2.17M |
|
25
Tyra Biosciences
TYRA
$675M
| $17.7M | 1.27% | +1,003,394 | New | +$17.7M |
|